Nexalin Q2 FY26 net loss widens 42% to $2.24 million; revenue drops 83% to $12,161

Reuters2026/08/12 21:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nexalin posted a net loss of USD 2.24 million, widening 42% year over year, as revenue slid 83% to USD 12,161.
Operating loss widened 39% to USD 2.25 million, while total operating expenses rose 35% to USD 2.26 million.
Research and development spending more than doubled to USD 564,480 on higher costs tied to the FDA insomnia clinical trial.
Professional fees jumped 128% to USD 407,444, reflecting higher accounting and legal costs tied to the PONM acquisition.
Nexalin completed the PONM acquisition, initiated its FDA-cleared Gen-3 HALO insomnia trial, and ended June 30 with cash of USD 1.01 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-008709), on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nexalin Q2 FY26 net loss widens 42% to $2.24 million; revenue drops 83% to $12,161

You may also like

Crypto prices